| Literature DB >> 35268244 |
Francesca Borgnis1,2, Francesca Baglio1, Elisa Pedroli3,4, Federica Rossetto1, Mario Meloni1, Giuseppe Riva2,3, Pietro Cipresso3,5.
Abstract
Recently, there has been an increasing interest in using 360° virtual-reality video for an ecologically valid assessment of executive functioning in the neurologic population. In this framework, we have developed the EXecutive-functions Innovative Tool (EXIT 360°), an original 360°-based instrument for a multicomponent, ecologically valid evaluation of executive functioning in Parkinson's Disease (PD). This work aimed to test the usability and user experience of EXIT 360° in patients with PD (PwPD). Twenty-seven PwPD and twenty-seven healthy controls underwent an evaluation that involved: (1) usability assessment by the System Usability Scale and (2) evaluation of user experience using the ICT-Sense of Presence and User Experience Questionnaire. Results showed a satisfactory level of usability for patients (mean = 76.94 ± 9.18) and controls (mean = 80 ± 11.22), with good scores for usability and learnability. Regarding user experience, patients provided a positive overall impression of the tool, evaluating it as attractive, enjoyable, activating, and funny. Moreover, EXIT 360° showed good pragmatic (e.g., efficient, fast, clear) and hedonic quality (e.g., exciting, interesting, and creative). Finally, PwPD considered EXIT 360° as an original tool with high ecological validity (mean = 4.29 ± 0.61), spatial presence (mean = 3.11 ± 0.83) and engagement (mean = 3.43 ± 0.54) without relevant adverse effects. Technological expertise had no impact on performance. Overall, EXIT 360° appeared to be a usable, easy-to-learn, engaging, and innovative instrument for PD. Further studies will be conducted to deepen its efficacy in distinguishing between healthy subjects and patients with executive dysfunctions.Entities:
Keywords: 360° environment; Parkinson’s disease; assessment; engagement; executive function; patients; usability; user experience; virtual reality
Year: 2022 PMID: 35268244 PMCID: PMC8911216 DOI: 10.3390/jcm11051153
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1A representation of a 360° environment that participants see in the headset (here, the image is represented in anamorphic format).
Figure 2The representation of the small white dot that participants see in the headset. To respond, participants must move their heads and position the dot on the answer for a few seconds and the answer will be selected automatically.
Questionnaire and scale to evaluate the user experience.
| Scale | Aim | Characteristics |
|---|---|---|
| 1. attractiveness (overall impression of the product) | a 26 item-scale (semantic differential scale: each item consists of two opposite adjectives, e.g., boring vs. exciting) that allows for calculation of the six different domains | |
| 1. spatial, physical presence: the feeling of being in a physical space in the virtual environment and having control over it | 44 item-scale | |
| perceived level of: | 5-point scale: from low to high | |
| participants’ appreciation of the proposed activity (i.e., boring, pleasant, fun and activating) | 5-point scale: from low to high |
Demographic and clinical characteristics of the whole sample.
| PwPD | HC | Group Comparison | |
|---|---|---|---|
| 68.2 (9) | 66.4 (10.5) | 0.507 | |
| 11:16 | 11:16 | 1.000 | |
| 13 (5) | 13 (5) | 0.740 | |
| 25.4 (3.12) | 26.3 (2.25) | 0.235 | |
| 25.3 (2.25) | 26.0 (2.53) | 0.246 |
M, male; F, female; SD, standard deviation; IQR, interquartile range; n, number; MoCA, Montreal Cognitive Assessment; PwPD, patients with Parkinson’s disease; HC, healthy controls.
Figure 3Percentages relating to familiarity with the technologies for each group. PD, Parkinson’s disease; HC, healthy control. 1 = never; 2 = once a month or more rarely; 3 = once a week; 4 = every 2/3 days; 5 = every day.
Figure 4Percentages relating to the self-reported competence in using several technologies for each group. PD, Parkinson’s disease; HC, healthy control.
Comparison of scores at EXIT 360°.
| PwPD | HC | Group Comparison | |
|---|---|---|---|
|
| 10.5 ± 1.58 | 12.3 ± 1.07 |
|
|
| 716.4 ± 174.19 | 457.3 ± 73.60 |
|
|
| 15.94 ± 2.33 | 17.46 ± 1.003 |
|
SD, standard deviation; PwPD, patients with Parkinson’s disease; HC, healthy controls; FAB = Frontal Assessment Battery (in bold, statistically significant value).
Figure 5A graphic representation of the SUS score. PD, Parkinson’s disease; HC, healthy control.
Comparison of scores at the subscale enjoyment of IMI.
| PwPD | HC | Group Comparison | |
|---|---|---|---|
|
| 5 (5) | 5 (5) | 0.107 |
|
| 4 (4–5) | 5 (4–5) | 0.113 |
|
| 5 (5) | 5 (5) | 0.28 |
|
| 4 (3.5) | 4 (4–4.5) | 0.81 |
IQR, interquartile range; n, number; PwPD, patients with Parkinson’s disease; HC, healthy controls.
Figure 6Graphic representation of the Intrinsic Motivation Inventory domains, comparing patients and controls.
Comparison of scores in ICT—SOPI dimensions.
| PwPD | HC | Group Comparison | |
|---|---|---|---|
|
| 3.11 ± 0.83 | 3.47 ± 0.48 | 0.054 |
|
| 3.43 ± 0.54 | 3.9 ± 0.47 |
|
|
| 4.29 ± 0.61 | 4.49 ± 0.37 | 0.149 |
|
| 1.29 ± 0.42 | 1.2 ± 0.26 | 0.361 |
SD, standard deviation; PwPD, patients with Parkinson’s disease; HC, healthy controls (in bold, statistically significant value).
Figure 7Graphic representation of two ICT—SOPI dimensions. The orange lines indicate a neutral score.
Figure 8Graphic representation of scores of the six UEQ scales.
Scores of the six UEQ scales. SD, standard deviation.
| Mean | SD | Confidence | Alpha- | ||
|---|---|---|---|---|---|
|
| 1.593 | 0.846 | 1.273 | 1.912 | 0.89 |
|
| 1.852 | 0.655 | 1.605 | 2.099 | 0.81 |
|
| 1.694 | 0.681 | 1.438 | 1.951 | 0.72 |
|
| 1.630 | 0.695 | 1.368 | 1.892 | 0.78 |
|
| 2.028 | 0.776 | 1.735 | 2.321 | 0.79 |
|
| 2.056 | 0.853 | 1.734 | 2.377 | 0.93 |
Comparison of scores in UEQ scales and dimensions.
| PwPD | HC | Group Comparison | |
|---|---|---|---|
|
| 1.59 (0.85) | 1.81 (1.13) | 0.430 |
|
| 1.85 (0.66) | 2.01 (0.75) | 0.416 |
|
| 1.69 (0.68) | 1.73 (0.84) | 0.859 |
|
| 1.63 (0.70) | 2.14 (0.86) |
|
|
| 2.03 (0.78) | 2.08 (0.98) | 0.818 |
|
| 2.06 (0.85) | 2.46 (0.68) | 0.058 |
|
| 1.73 (0.59) | 1.96 (0.74) | 0.204 |
|
| 2.04 (0.72) | 2.27 (0.82) | 0.275 |
SD, standard deviation; PwPD, patients with Parkinson’s disease; HC, healthy controls (in bold, statistically significant value).
Figure 9Comparison between means of each UEQ scale and values from a benchmark dataset.